<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645069</url>
  </required_header>
  <id_info>
    <org_study_id>ADG126-1001</org_study_id>
    <nct_id>NCT04645069</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies</brief_title>
  <official_title>First-in-human (FIH), Open-Label, Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagene Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagene Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic&#xD;
      tumors. Study drug, ADG126 is an anti -CTLA-4 fully human monoclonal antibody that&#xD;
      specifically binds to human CTLA-4. ADG126 administered intravenously (IV) over a period of&#xD;
      60-90 minutes. The study is planned to treat up to 100 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">April 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic tumors</measure>
    <time_frame>From first dose of ADG126 (Week 1 Day 1) until 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>From first dose of ADG126 (Week 1 Day 1) to 28 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the time concentration curve (AUC) from time zero to infinity (AUC0-inf)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (peak) plasma concentration (Cmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum (peak) plasma concentration (Tmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced/Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>ADG126 Dose Escalation Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG126 Dose Escalation Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG126 Dose Escalation Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG126 Dose Escalation Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG126 Dose Escalation Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADG126</intervention_name>
    <description>ADG126 will be administered IV over 60-90 minutes with planned doses every three weeks for the first 4 cycles. If no intolerable toxicities occur during the first consecutive 4 treatment cycles, administration of ADG126 may continue every 3 weeks (Q3W) for up to 2 years per agreement with investigator and medical monitor.</description>
    <arm_group_label>ADG126 Dose Escalation Level 1</arm_group_label>
    <arm_group_label>ADG126 Dose Escalation Level 2</arm_group_label>
    <arm_group_label>ADG126 Dose Escalation Level 3</arm_group_label>
    <arm_group_label>ADG126 Dose Escalation Level 4</arm_group_label>
    <arm_group_label>ADG126 Dose Escalation Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Histologically or cytologically documented, incurable or metastatic malignacies that&#xD;
             is advanced (non-resectable) or recurrent and progressing since the last anti-tumor&#xD;
             therapy and for which no recognized standard therapy exists or for which standard of&#xD;
             care has been declined (with reason to be clearly documented)&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Willing to complete all scheduled visits and assessments at the institution&#xD;
             administering therapy&#xD;
&#xD;
          -  Able to read, understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt; 3 months, as determined by the Investigator&#xD;
&#xD;
          -  Treatment with any local or systemic antineoplastic therapy (including chemotherapy,&#xD;
             hormonal therapy, radiation, or immunotherapy) within 3 weeks prior to first dose of&#xD;
             ADG126, with the following exceptions:&#xD;
&#xD;
          -  Major trauma or major surgery within 4 weeks prior to first dose of ADG126&#xD;
&#xD;
          -  Adverse events (AEs) from prior anti-cancer therapy that have not resolved to Grade ≤&#xD;
             1 except for alopecia or irAE of immunotherapy resulted in permanent discontinuation.&#xD;
&#xD;
          -  Central nervous system disease involvement, or prior history of NCI CTCAE Grade ≥ 3&#xD;
             drug-related CNS toxicity&#xD;
&#xD;
          -  Evidence of active uncontrolled viral, bacterial, or systemic fungal infection defined&#xD;
             as requiring use of systemic antimicrobials within 2 weeks of enrollment; prophylactic&#xD;
             therapy according to institutional protocols is acceptable&#xD;
&#xD;
          -  Known positive test result for human immunodeficiency virus (HIV) or acquired immune&#xD;
             deficiency syndrome (AIDS)&#xD;
&#xD;
          -  Active hepatitis C virus (HCV) or hepatitis B virus (HBV) requiring treatment;&#xD;
&#xD;
          -  History (within the last 5 years) or risk of autoimmune disease (e.g., autoimmune&#xD;
             thyroid disease, Bell's palsy, glomerulonephritis, Guillain-Barré syndrome,&#xD;
             inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, Sjögren's&#xD;
             syndrome, systemic lupus erythematosus, vascular thrombosis associated with&#xD;
             antiphospholipid syndrome, vasculitis, or Wegener's granulomatosis)&#xD;
&#xD;
          -  Any serious underlying medical (e.g., pulmonary, renal, hepatic, gastrointestinal, or&#xD;
             neurological) or psychiatric condition (e.g. alcohol or drug abuse, dementia or&#xD;
             altered mental status) or any issue that would that would limit compliance with study&#xD;
             requirements, impair the ability of the patient to understand informed consent, or&#xD;
             that in the opinion of the investigator would contraindicate the patient's&#xD;
             participation in the study or confound the results of the study&#xD;
&#xD;
          -  Known hypersensitivity, allergies, or intolerance to immunoglobulins or to any&#xD;
             excipient contained in ADG126 (see Investigator's Brochure)&#xD;
&#xD;
          -  Pregnant, lactating, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul De Souza, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southside Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Richardson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cabrini Private Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Morris, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunshine Coast University Private Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohong She</last_name>
    <phone>4088389296</phone>
    <email>kristine_she@adagene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Gong, MD</last_name>
    <phone>8586954033</phone>
    <email>hua_gong@adagene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southside Cancer Care Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul De Souza, Professor</last_name>
      <phone>0295539588</phone>
      <email>P.DeSouza@westernsydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Private Hospital</name>
      <address>
        <city>Sunshine Coast</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Morris, Professor</last_name>
      <phone>0754377633</phone>
      <email>MorrisMi2@ramsayhealth.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabrini Health Limited</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Richardson, Professor</last_name>
      <phone>1300300977</phone>
      <email>gary.richardson@ocv.net.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>May 16, 2021</last_update_submitted>
  <last_update_submitted_qc>May 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced/Metastatic Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

